Fig. 3

Analysis by flow cytometry of the peripheral blood mononuclear cells showed that the population of immunosenescent T cells with a phenotype CD8⁺CD28⁻ was 46.2% in this patient (a), 30.7% in another 72-year-old patient with breast cancer with bone metastases who had no previous treatment with and was currently being treated with abemaciclib (b), 46.4% in a healthy volunteer (c), and 64.8% in a patient with recurrent breast cancer treated with multiple cytotoxic agents (d). Blue circles indicated the population of immunosenescent T cells (CD8⁺CD28⁻)